NPI 1780750299: Open Payments
NPI 1780750299. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,423 in 84 payments from 10 companies in 2025. Trend: 2023 $1,014 · 2024 $1,938 · 2025 $1,423
Food & beverage: $1,423
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $301 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $284 |
| Otsuka America Pharmaceutical, Inc. | 15 | $212 |
| Alkermes, Inc. | 7 | $141 |
| Lundbeck LLC | 6 | $140 |
| Vanda Pharmaceuticals Inc. | 9 | $140 |
| Janssen Pharmaceuticals, Inc | 3 | $101 |
| Axsome Therapeutics, Inc. | 3 | $64 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $18 |
Products named: REXULTI, VRAYLAR, CAPLYTA, FANAPT, INVEGA SUSTENNA, ARISTADA, LYBALVI, Auvelity.
